Cliff Asness's RMD Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 222.1K shares of ResMed Inc. (RMD) worth $60.77 M, representing 0.04% of the portfolio. First purchased in 2012-Q4, this long-term strategic position has been held for 52 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in RMD, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2018, adding 535.8K shares. Largest reduction occurred in Q1 2019, reducing 309.8K shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's ResMed (RMD) Holding Value Over Time
Track share changes against reported price movement
Quarterly ResMed (RMD) Trades by Cliff Asness
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2012 | +331,101 | Add 0.00% | 331,100 | $41.57 |
| Q2 2013 | +367,501 | Add 0.00% | 367,500 | $45.13 |
| Q3 2013 | +5,929 | Add 1.61% | 373,429 | $52.82 |
| Q4 2013 | +40,159 | Add 10.75% | 413,588 | $47.08 |
| Q1 2014 | -5,700 | Reduce 1.38% | 407,888 | $44.69 |
| Q2 2014 | -10,300 | Reduce 2.53% | 397,588 | $50.63 |
| Q3 2014 | -172,700 | Reduce 43.44% | 224,888 | $49.27 |
| Q4 2014 | -19,005 | Reduce 8.45% | 205,883 | $56.06 |
| Q1 2015 | -24,445 | Reduce 11.87% | 181,438 | $71.78 |
| Q2 2015 | -58,192 | Reduce 32.07% | 123,246 | $56.37 |
| Q3 2015 | +63,613 | Add 51.61% | 186,859 | $50.96 |
| Q4 2015 | +186,287 | Add 99.69% | 373,146 | $53.69 |
| Q1 2016 | +25,460 | Add 6.82% | 398,606 | $57.82 |
| Q2 2016 | +163,666 | Add 41.06% | 562,272 | $63.23 |
| Q3 2016 | -60,136 | Reduce 10.70% | 502,136 | $64.79 |
| Q4 2016 | -86,087 | Reduce 17.14% | 416,049 | $62.05 |
| Q1 2017 | -23,546 | Reduce 5.66% | 392,503 | $71.97 |
| Q2 2017 | -54,465 | Reduce 13.88% | 338,038 | $77.87 |
| Q3 2017 | -39,825 | Reduce 11.78% | 298,213 | $76.96 |
| Q4 2017 | +66,416 | Add 22.27% | 364,629 | $84.69 |
| Q1 2018 | -28,207 | Reduce 7.74% | 336,422 | $98.47 |
| Q2 2018 | +17,225 | Add 5.12% | 353,647 | $103.58 |
| Q3 2018 | +535,803 | Add 151.51% | 889,450 | $115.34 |
| Q4 2018 | +74,232 | Add 8.35% | 963,682 | $113.87 |
| Q1 2019 | -309,809 | Reduce 32.15% | 653,873 | $103.43 |
| Q2 2019 | -182,071 | Reduce 27.85% | 471,802 | $120.83 |
| Q3 2019 | -69,068 | Reduce 14.64% | 402,734 | $135.11 |
| Q4 2019 | -113,881 | Reduce 28.28% | 288,853 | $154.29 |
| Q1 2020 | -24,003 | Reduce 8.31% | 264,850 | $147.29 |
| Q2 2020 | -32,580 | Reduce 12.30% | 232,270 | $189.54 |
| Q3 2020 | +110,908 | Add 47.75% | 343,178 | $171.43 |
| Q4 2020 | -2,889 | Reduce 0.84% | 340,289 | $209.15 |
| Q1 2021 | +18,840 | Add 5.54% | 359,129 | $193.53 |
| Q2 2021 | -51,168 | Reduce 14.25% | 307,961 | $245.77 |
| Q3 2021 | -64,509 | Reduce 20.95% | 243,452 | $263.55 |
| Q4 2021 | +12,402 | Add 5.09% | 255,854 | $260.48 |
| Q1 2022 | -85,459 | Reduce 33.40% | 170,395 | $242.51 |
| Q2 2022 | -74,266 | Reduce 43.58% | 96,129 | $209.63 |
| Q3 2022 | -17,829 | Reduce 18.55% | 78,300 | $218.30 |
| Q4 2022 | +7,069 | Add 9.03% | 85,369 | $206.00 |
| Q1 2023 | -12,917 | Reduce 15.13% | 72,452 | $217.29 |
| Q2 2023 | +14,285 | Add 19.72% | 86,737 | $218.50 |
| Q3 2023 | +20,165 | Add 23.25% | 106,902 | $147.87 |
| Q4 2023 | -10,105 | Reduce 9.45% | 96,797 | $172.02 |
| Q1 2024 | +46,448 | Add 47.98% | 143,245 | $197.75 |
| Q2 2024 | +29,538 | Add 20.62% | 172,783 | $191.42 |
| Q3 2024 | +94,805 | Add 54.87% | 267,588 | $244.12 |
| Q4 2024 | +357,466 | Add 133.59% | 625,054 | $228.69 |
| Q1 2025 | -222,638 | Reduce 35.62% | 402,416 | $219.15 |
| Q2 2025 | -215,870 | Reduce 53.64% | 186,546 | $256.28 |
| Q3 2025 | +35,565 | Add 19.07% | 222,111 | $273.59 |
Cliff Asness's ResMed Investment FAQs
Cliff Asness first purchased ResMed Inc. (RMD) in Q4 2012, acquiring 331,100 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held ResMed Inc. (RMD) for 52 quarters since Q4 2012. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's largest addition to ResMed Inc. (RMD) was in Q3 2018, adding 889,450 shares worth $102.59 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 222,111 shares of ResMed Inc. (RMD), valued at approximately $60.77 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, ResMed Inc. (RMD) represents approximately 0.04% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's peak holding in ResMed Inc. (RMD) was 963,682 shares, as reported at the end of Q4 2018. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.